Santhera Pharmaceuticals (Schweiz) AG

The sponsor’s trial portfolio includes work on vamorolone in boys with Duchenne muscular dystrophy, highlighting interest in treatment strategies that address chronic disease management and safety in extended use. The clinical focus includes outcomes relevant to ongoing care, such as bone health and fracture risk in children receiving long-term therapy.

• Long-term treatment safety
• Bone health
• Vertebral fractures

This area reflects attention to the complications associated with sustained treatment in paediatric neuromuscular disease.

Santhera also supports research in healthy male volunteers to characterise how vamorolone behaves in the body, with interest in pharmacokinetics and CYP3A4-related interactions. This indicates a therapeutic development focus that extends beyond the target disease population to the broader assessment of drug disposition and metabolic pathways.

• Pharmacokinetics
• CYP3A4 induction
• Healthy volunteer studies

The sponsor’s research activity in this domain supports understanding of how the treatment is processed and interacts with other medicines.

The company’s clinical research landscape is concentrated in rare disease medicine, particularly disorders affecting skeletal muscle and mobility. Its funded trials connect disease-specific treatment development with safety assessment and tolerability evaluation, underscoring a strong medical interest in chronic, genetically driven neuromuscular conditions.

• Rare disease therapeutics
• Skeletal muscle disorders
• Mobility impairment

These activities align with ongoing clinical investigation in Europe and multiple international study sites.